Aegerion Upbeat On Juxtapid Launch, Stares Down PCSK9 Threat
This article was originally published in The Pink Sheet Daily
Executive Summary
Aegerion said the U.S. launch of Juxtapid in its initial HoFH population was going according to plan. Management spoke of a few upside surprises, including the high number of prescribing cardiologists and recently released data showing the PCSK9 class may be inadequate in this orphan indication.